Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8NAU1
UPID:
FNDC5_HUMAN
Alternative names:
Fibronectin type III repeat-containing protein 2
Alternative UPACC:
Q8NAU1; A6NMC9; D3DPQ6; Q6P6D9; Q7Z676
Background:
Fibronectin type III domain-containing protein 5, alternatively known as Fibronectin type III repeat-containing protein 2, plays a unique role in human physiology. Unlike in mice, it appears not to contribute to the positive outcomes of physical exercise or the conversion of white adipose tissue into brown adipose tissue in humans.
Therapeutic significance:
Understanding the role of Fibronectin type III domain-containing protein 5 could open doors to potential therapeutic strategies.